Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study
Authors' conclusion
Ipragliflozin add-on therapy can be a viable option for better glycaemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulphonylurea.
Study context
- Population
- Patients with T2D inadequately controlled with metformin and SU, HbA1c 7.5%-9.0%
- Participants
- 70 vs 70
- Comparison
- Ipragliflozin vs sitagliptin as add-on to metformin and SU
- Ipragliflozinn = 70
- Sitagliptinn = 70reference
- Primary endpoint
- Glucose-lowering efficacy (HbA1c)
- Follow-up
- 24 weeks
Primary result
Mean HbA1c
Between-group difference
0.34 %
95% CI 0.10%–0.43%
P = 0.088
By group
Between Ipragliflozin and Sitagliptin
between-group difference 0.34 % (95% CI 0.10%–0.43%); P = 0.088
As reported in the abstract
Further findings
Fasting and postprandial 2-h glucose
- Similar trend, with greater reduction with ipragliflozin
Ketones, fat mass and fatty liver indices
- Increase in ketone levels with ipragliflozin
- over 70%
- Decrease in whole body and abdominal fat masses with ipragliflozin
- Fatty liver indices improved with ipragliflozin
Vascular measures
- No difference in carotid intima-media thickness and ankle-brachial index
- Ipragliflozin improved flow-mediated vasodilation; sitagliptin did not
Safety
- Safety profile did not differ between the two groups
Original publication
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. Diabetes Obes Metab. Published 4 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →